Core Viewpoint - Flagstar Financial, Inc. has announced a merger agreement with Flagstar Bank, where the Company will merge into the Bank, simplifying its organizational structure and operations [1][2][4] Group 1: Merger Details - The merger will result in Flagstar Bank, N.A. as the surviving entity, with its common stock continuing to trade under the ticker symbol "FLG" on the NYSE [1] - The reorganization aims to reduce costs, streamline operations, and eliminate redundant corporate activities [2] Group 2: Approval Process - The merger is subject to regulatory and shareholder approval, with a proxy statement expected to be filed with the SEC in Q3 2025 [3] - The Company anticipates completing the merger before the end of 2025, assuming all approvals are received [3] Group 3: Company Overview - As of March 31, 2025, Flagstar Financial, Inc. had $97.6 billion in assets, $67.1 billion in loans, $73.9 billion in deposits, and total stockholders' equity of $8.2 billion [4] - Flagstar Bank operates approximately 400 locations across nine states, with a strong presence in the New York/New Jersey metropolitan area and significant markets in Florida and the West Coast [4]

Core Viewpoint - Jasper Therapeutics is undergoing a significant corporate reorganization, including a workforce reduction of approximately 50%, to extend its cash runway and focus on the development of briquilimab for chronic urticaria [1][6]. Company Updates - The company is halting all other clinical and preclinical programs to concentrate resources on briquilimab, which targets mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [1][6]. - Dr. Edwin Tucker is departing as Chief Medical Officer, with Dr. Daniel Adelman stepping in as Acting Chief Medical Officer [1][6]. Product Development - Briquilimab is a novel antibody therapy that inhibits signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in mast cell-driven diseases [5][7]. - The company has reported rapid, deep, and durable responses along with a favorable safety profile for briquilimab in both CSU and CIndU [2][6]. Future Plans - Jasper plans to share additional data from the BEACON and open label extension studies later in the year, indicating ongoing commitment to briquilimab's development despite the operational streamlining [2][6].

Core Viewpoint - Starcore International Mines Ltd. plans to spin out its exploration interests in Côte d'Ivoire to a wholly-owned subsidiary, EU Gold Mining Inc., allowing the company to focus on its Mexican gold and silver assets while EU Gold develops the African properties [1][2][3]. Group 1: Spin-Out Details - The spin-out will involve transferring all mineral property assets in Africa to EU Gold, which will seek a separate listing in Canada [2]. - EU Gold will assume all liabilities related to the African properties and will issue one common share for every two shares of Starcore, resulting in Starcore receiving approximately 33,431,758 shares of EU Gold to distribute to its shareholders [3]. Group 2: Management and Strategy - The goal of the spin-out is to maximize shareholder value by allowing each entity to focus on its major assets, with EU Gold expected to attract new management experienced in African diplomacy and culture [3]. - Starcore's management will concentrate on its existing operations in Mexico, enhancing its focus on precious metals production [5]. Group 3: Regulatory and Approval Process - The Plan of Arrangement for the spin-out is subject to shareholder and regulatory approvals [4].

Corporate Update - Search Minerals Inc. has announced a corporate update including the reinstatement of trading on the TSX Venture Exchange (TSXV) expected around June 17, 2025 [4] - The company faced a cease trade order (CTO) due to failure to file annual audited financial statements for the year ended November 30, 2023 [2][3] - A new Board of Directors was elected on June 21, 2024, to address management issues and has since worked to remedy the company's situation [3] Financial Position - The company's interim financial statements for the three months ended February 28, 2025, show a working capital deficiency of $5,282,051 [6] - The deficiency is primarily due to accounts payable and accrued liabilities totaling $2,885,836 and other debts [7] - The company plans to seek financing through a private placement to return to a positive working capital position [11] Financing and Debt - Search Minerals intends to conduct a non-brokered private placement to raise approximately $12 million, with each unit consisting of one share and one warrant [11] - The company has entered into a loan agreement for an unsecured loan of $750,000 to support its operations [16][17] - The loan bears an interest rate of 15% per annum and is payable by August 30, 2026, or upon closing of any financing exceeding $2.5 million [17] Share Consolidation - The company plans to consolidate its shares on a basis of ten pre-consolidation shares for one post-consolidation share, reducing the number of outstanding shares from approximately 417.99 million to about 41.80 million [18][19] - The consolidation is expected to take effect on or about June 17, 2025 [18] Annual General Meeting - The company intends to hold its annual general meeting on July 24, 2025, to comply with TSXV Policy 3.1 [25] - The last annual meeting was held on May 25, 2022, and the company has not been in compliance since then [23][24] Management Changes - The new Board appointed Joseph Lanzon as CEO and Greg Andrews as CFO and Corporate Secretary, although Andrews resigned later [27] - The company is currently not in compliance with TSXV Policy 3.1 regarding management structure and audit committee requirements [26][27]